Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium

Bergstrom, Debra; Kotb, Rami; Louzada, Martha L; Sutherland, Heather J.; Tavoularis, Stavros; Venner, Christopher P.; Côté, Johanne; LeBlanc, Richard; Reiman, Anthony; Sébag, Michaël; Song, Kevin; Colasurdo, Gabriele; Col, Aldo Del; McMullen, David P.; Hay, Annette E.; Laferriere, Nicole M.B.; McCurdy, Arleigh; Roy, Jean; Stakiw, Julie; Trudel, Suzanne; White, Darrell; Loveys, Fraser W.; Randell, Edward; Rizkalla, Kamilia

doi:10.1016/j.clml.2020.01.017

Cited by 33 publications

(31 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The emergence of targeted new drugs has greatly improved the quality of life of MM patients. However, for the early diagnosis of MM, that is, after the patient has bone pain, clinicians obviously cannot make a timely and accurate diagnosis based on traditional imaging examinations, which leads to the development of the patient's condition and delays the treatment [36] . Bone marrow biopsy is the traditional gold standard for diagnosis, but it is an invasive test that is very painful for patients.…”

Section: Discussionmentioning

confidence: 99%

Potential diagnostic value of circulating miRNA for multiple myeloma: A meta-analysis

Gao

Wang²,

Zhang

et al. 2020

Journal of Bone Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Potential diagnostic value of circulating miRNA for multiple myeloma: A meta-analysis

Gao

Wang²,

Zhang

et al. 2020

Journal of Bone Oncology

View full text Add to dashboard Cite

show abstract

“…The emergence of targeted new drugs has greatly improved the quality of life of MM patients. However, for the early diagnosis of MM, that is, after the patient has bone pain, clinicians obviously cannot make a timely and accurate diagnosis based on traditional imaging examinations, which leads to the development of the patient's condition and delays the treatment [37] . Bone marrow biopsy is the traditional gold standard for diagnosis, but it is an invasive test that is very painful for patients.…”

Section: Discussionmentioning

confidence: 99%

Potential Diagnostic Value of Circulating miRNA for Multiple Myeloma: A Meta-Analysis.

Zhang

Gao

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Multiple myeloma (MM) is the second incurable hematological malignancy. In recent years, due to the rise of microRNA (miRNA), many scholars have participated in the study of its value in the diagnosis of MM, and have obtained good but inconsistent results. Therefore, in order to determine the role of miRNA in the early diagnosis of MM, we searched for related studies including PubMed, Web of Science, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI) and Wanfang Database as of July 20, 2020 to conduct this meta-analysis. To improve the accuracy, the quality assessment of Diagnostic Accuracy Study 2 (QUADAS-2) was used. We also applied random effects models to summarize sensitivity and specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the curve (AUC) to measure diagnostic values, and subgroup analysis used to discover potential sources of heterogeneity. Finally, we collected 32 studies from 15 articles that included a total of 2053 MM patients and 1118 healthy controls. The overall sensitivity, specificity, PLR, NLR, DOR and AUC were 0.81, 0.85, 5.5, 0.22, 25 and 0.90, respectively. Subgroup analysis shows that the down-regulation of microRNA clusters with larger samples size of plasma type could carry out a better diagnostic accuracy of MM patients. In addition, publication bias was not found. In conclusion, circulating miRNA could be a potential non-invasive biomarker for early diagnosis of MM. However, multi-center, more rigorous, and larger-scale studies are needed to verify our conclusions.

show abstract

“…However, with the current COVID-19 pandemic, many trials are not accepting new patients, and thus these patients should be monitored and observed. 24,25 MGUS patients should be evaluated regularly to detect early transformation to initiate the treatment, minimize major complications, and prolong survival. Testing of M-proteins can be added for other routine medical tests.…”

Section: Approach To Newly Diagnosed Mgus and Smm Patientsmentioning

confidence: 99%

Untitled

2021

Asian Journal of Oncology

View full text Add to dashboard Cite

Introduction Coronavirus disease 2019 (COVID-19) has become a world pandemic since early 2020. The complexity of handling multiple myeloma (MM) has increased substantially during this pandemic. The objective of this review is to know the current recommendation to manage MM in the COVID-19 era. Materials and Methods Electronic databases, including PubMed central and PubMed, were used to conduct a literature search. It was conducted on May 18, 2020, using the keywords "multiple myeloma" AND "COVID-19" AND "Prevalence OR Impact OR treatment OR prophylactic." The included articles were review articles, recommendations, case reports or series, or population-based studies (cross-sectional, cohort, case-control, or interventional), and full-text if available. Results A total of 124 articles were identified through the search strategy. The two reviewers screened titles and abstracts of all articles. Most articles were excluded because of ineligible to the criteria. Ultimately, 18 articles were included in the final evaluation. MM patients might have higher risk to become severe COVID-19 if they got infected due to their immunocompromised condition. Due to the pandemic, precise treatment priorities should be made by considering its benefit and the risk of MM progression. For the young, especially healthy patients, the most effective therapy should be offered and tailored to the patient's goal. Several MM societies have published the recommendation regarding the special stage of MM. Conclusion Myeloma societies in the world have released recommendations related to the management of myeloma patients. However, there is scarce of evidence to do the recommendation.

show abstract

Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium

Cited by 33 publications

References 97 publications

Potential diagnostic value of circulating miRNA for multiple myeloma: A meta-analysis

Potential diagnostic value of circulating miRNA for multiple myeloma: A meta-analysis

Potential Diagnostic Value of Circulating miRNA for Multiple Myeloma: A Meta-Analysis.

Untitled

Contact Info

Product

Resources

About